golf stud, The market gives AMRN zero credit for having what may eventually become a standard of treatment for the residual inflammation that affects many patients who have had COVID-19. Heck, even if it were not sold for such a use in the US, Europe and China would still make two massive potential markets...but again, only if BP is owns it. GIA in Europe would be laughable.